Moderna

19 Decision Makers Β· 26 Verified Contacts & Email Format

πŸ“ Cambridge, MABiotechnologyπŸ—“ Est. 2010πŸ‘₯ 1001–5000 employees

About Moderna

Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.

Email Format

{first_name}.{last_name}@modernatx.com β€” 100.0%

sarah.smith@modernatx.com

Leadership & Decision Makers

Contact details of 19 Moderna decision makers

Kerry Salandria

Associate Director, Analytical Operations LinkedIn
  • Work email

    k*************a@modernatx.com

Dean Geribo

Head of Corporate Security LinkedIn
  • Work email

    d*********o@modernatx.com

Michael Wythe

Senior Director LinkedIn
  • Work email

    m***********e@modernatx.com

Spyros Chalkias

Senior Medical Director, Clinical Development, Infectious Disease - Public Health Vaccines LinkedIn
  • Work email

    s*************s@modernatx.com

Galit Alter

VP of Immunology Research LinkedIn
  • Work email

    g*********r@modernatx.com

Francesca Ceddia

SVP Respiratory Vaccines, Global Medical LinkedIn
  • Work email

    f**************a@modernatx.com

Seymour De Picciotto

Scientific Director LinkedIn
  • Work email

    s*****************o@modernatx.com

Tatiana Novobrantseva

Chief Scientific Officer, Immuno-Oncology Research
  • Work email

    t*******************a@modernatx.com

  • Personal email

    tatiana.novobrantseva@gmail.com

Juan Andres

Senior Vice President Technical Development, Manufacturing and Quality
  • Work email

    j*********s@modernatx.com

Nidal El Assi

Associate Director Of Lab Operations
  • Work email

    n********i@modernatx.com

Shannon Thyme Klinger

Chief Legal Officer at Moderna
  • Work email

    s*************r@modernatx.com

Noubar Afeyan

Chairman & Co-Founder

Stephen Hoge

President

Stephane Bancel

President and Founding CEO
Associate Director, Analytical Development

Timothy A. Springer

Co-Founder

Eric Ma

Principal Data Scientist

Derrick Rossi

Founder

Kenneth Chien

Founder

Team & Specialists

Contact details of 7 Moderna team members

Huijuan Li

Head, Analytical Development LinkedIn
  • Work email

    h********i@modernatx.com

Tina Earl

Sr. Specialist, Quality Assurance LinkedIn
  • Work email

    t*******l@modernatx.com

Lilly Naqvi

Engineer II LinkedIn
  • Work email

    l*********i@modernatx.com

Lavina Talukdar

  • Work email

    l*************r@modernatx.com

Gamal Elfatarany

  • Work email

    g**************y@modernatx.com

Kate Jeffrey

  • Work email

    k**********y@modernatx.com

Katriona Methven

  • Work email

    k**************n@modernatx.com

General Emails

General company emails, e.g. customer support lines

    WeCare@modernatx.com

    Unclassified inbox

    Grace.Chen@modernatx.com

    Unclassified inbox

    info@modernatx.com

    General Inquiries

    stephane.bancel@modernatx.com

    Unclassified inbox

    careers@modernatx.com

    Unclassified inbox

Similar Companies like Moderna

Seagen

seagen.com
Biotechnology Β· Bothell, Washington, United States Β· Est. 1998 Β· 1001–5000 employees Β· $500M–$1B

HQ: Bothell, Washington, United States

Biotechnology Β· Boston, MA Β· Est. 1989 Β· 1001–5000 employees Β· $500M–$1B

HQ: Boston, MA

Fulgent Therapeutics

fulgentgenetics.com
Biotechnology Β· Temple City, California, United States Β· Est. 2011 Β· 1001–5000 employees

HQ: Temple City, California, United States

Horizon Pharma

horizontherapeutics.com
Pharmaceuticals Β· Northbrook, Illinois, United States Β· Est. 2005 Β· 1001–5000 employees

HQ: Northbrook, Illinois, United States

KBI Biopharma

kbibiopharma.com
Pharmaceuticals Β· Durham, NC Β· Est. 1996 Β· 1001–5000 employees Β· $500M–$1B

HQ: Durham, NC

Explore similar firms in the Biotechnology sector

Company Info

Last updated: 27/07/2025

617-714-6500

Cambridge, MA

Specialization: Genetics,
Legal Name: Moderna, Inc.
Business Type: Public
Employees: 1001-5000
Rounds: Post-IPO Equity
Founded Date: 2010
Number of Exits: 3
Company Type: For Profit
Stock Symbol: NASDAQ:MRNA
Operating Status: Active
Investor Type: Investment Bank
Last Funding Type: Post-IPO Equity
Phone Number: 617-714-6500
Last Investment Activity: Mar 15, 2024
Investments Activity: Mar 15, 2024 Mar 14, 2024 Mar 13, 2024

Our service is undergoing beta testing, and you can get all the information that is closed on this page for free by registering. You will not need to provide your credit/debit card details.